Oral Prenylation Inhibition With Lonafarnib in Chronic Hepatitis D Infection: A Randomized, Double-Blinded, Placebo-Controlled Proof-of-Concept Study
Background: Interferon therapy for chronic delta hepatitis (HDV) infection is unsatisfactory. In in vivo models, prenylation inhibition has proven effectiveness against HDV. In a first-in-human for HDV, proof-of-concept study, we evaluated the antiviral effects and safety of the prenylation inhibitor, lonafarnib (LNF), in patients with chronic HDV. Methods: HDV patients were sequentially enrolled into 2…